Ubs Group Ag Corvus Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 162,074 shares of CRVS stock, worth $1.42 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

162,074

Previous 89,714 80.66%

Holding current value

$1.42 Million

Previous $358,000 224.02%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$3.86 - $7.39 $279,309 - $534,740	72,360 Added 80.66%	162,074 $1.16 Million
Q2 2025 Aug 14, 2025	BUY	$2.82 - $4.5 $150,362 - $239,940	53,320 Added 146.51%	89,714 $358,000
Q1 2025 May 13, 2025	SELL	$3.18 - $6.03 $49,973 - $94,761	-15,715 Reduced 30.16%	36,394 $115,000
Q4 2024 Feb 14, 2025	BUY	$4.55 - $9.56 $165,747 - $348,251	36,428 Added 232.31%	52,109 $270,000
Q3 2024 Nov 14, 2024	BUY	$1.78 - $5.92 $4,772 - $15,871	2,681 Added 20.62%	15,681 $82,000

Q2 2024 Aug 13, 2024	BUY	$1.36 - $2.29 $11,316 - $19,055	8,321 Added 177.84%	13,000 $23,000
Q1 2024 May 13, 2024	SELL	$1.76 - $2.41 $3,556 - $4,870	-2,021 Reduced 30.16%	4,679 $8,000
Q2 2023 Aug 11, 2023	SELL	$1.0 - $3.86 $4,314 - $16,652	-4,314 Reduced 39.17%	6,700 $15,000
Q1 2023 May 12, 2023	BUY	$0.65 - $0.92 $4,104 - $5,808	6,314 Added 134.34%	11,014 $10,000
Q4 2022 Feb 08, 2023	SELL	$0.74 - $1.04 $13,287 - $18,674	-17,956 Reduced 79.25%	4,700 $3,000
Q3 2022 Nov 10, 2022	BUY	$0.71 - $1.17 $60 - $99	85 Added 0.38%	22,656 $18,000
Q2 2022 Aug 10, 2022	BUY	$0.87 - $2.03 $7,363 - $17,181	8,464 Added 60.0%	22,571 $22,000
Q1 2022 May 16, 2022	BUY	$1.46 - $2.48 $7,062 - $11,995	4,837 Added 52.18%	14,107 $23,000
Q4 2021 Feb 14, 2022	BUY	$2.34 - $5.31 $14,671 - $33,293	6,270 Added 209.0%	9,270 $22,000
Q1 2021 May 12, 2021	SELL	$2.86 - $4.77 $20,142 - $33,595	-7,043 Reduced 70.13%	3,000 $9,000
Q4 2020 Feb 11, 2021	BUY	$3.56 - $4.86 $20,434 - $27,896	5,740 Added 133.4%	10,043 $36,000
Q3 2020 Nov 12, 2020	BUY	$2.6 - $5.37 $9,318 - $19,246	3,584 Added 498.47%	4,303 $17,000
Q2 2020 Jul 31, 2020	SELL	$2.01 - $4.05 $4,214 - $8,492	-2,097 Reduced 74.47%	719 $2,000
Q1 2020 May 01, 2020	BUY	$1.74 - $5.98 $4,899 - $16,839	2,816 New	2,816 $6,000
Q3 2019 Nov 14, 2019	SELL	$3.01 - $6.5 $51 - $110	-17 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$3.3 - $4.58 $18,176 - $25,226	-5,508 Reduced 99.69%	17 $0
Q1 2019 May 14, 2019	SELL	$3.75 - $4.97 $3,251 - $4,308	-867 Reduced 13.56%	5,525 $22,000
Q4 2018 Feb 14, 2019	BUY	$3.29 - $8.94 $21,029 - $57,144	6,392 New	6,392 $23,000
Q2 2018 Aug 14, 2018	SELL	$9.42 - $13.73 $16,729 - $24,384	-1,776 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$7.48 - $11.53 $56,331 - $86,832	-7,531 Reduced 80.92%	1,776 $20,000
Q4 2017 Feb 14, 2018	BUY	$9.3 - $16.93 $74,186 - $135,050	7,977 Added 599.77%	9,307 $96,000
Q3 2017 Nov 14, 2017	BUY	$11.3 - $17.23 $15,029 - $22,915	1,330 New	1,330 $21,000
Q2 2017 Aug 14, 2017	SELL	N/A	-698 Closed	0 $0
Q1 2017 Nov 14, 2017	BUY	N/A	698	698 $15,000

Others Institutions Holding CRVS

# of Institutions

109

Shares Held

38.3M

Call Options Held

198K

Put Options Held

167K

View Full List

About Corvus Pharmaceuticals, Inc.

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $408M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

More about CRVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account